1-8 of 8
Pamela Munster
Close
Sort by
Journal Articles

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Clinical Trials & Observations
Thomas Martin, Rachid Baz, Don M. Benson, Nikoletta Lendvai, Jeffrey Wolf, Pamela Munster, Alexander M. Lesokhin, Claudine Wack, Eric Charpentier, Frank Campana, Ravi Vij
Journal: Blood
Blood (2017) 129 (25): 3294–3303.
https://doi.org/10.1182/blood-2016-09-740787
Published: 2017
Journal Articles

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Thomas G. Martin, III, MD, Gabriel N Mannis, Ajai Chari, MD, Pamela Munster, MD, Frank Campana, MD, Ai-Min Hui, MD PhD, Jeffrey L. Wolf, MD
Journal: Blood
Blood (2016) 128 (22): 2111.
https://doi.org/10.1182/blood.V128.22.2111.2111
Published: 2016
Journal Articles

Panobinostat-Augmented Cytarabine and Daunorubicin (7+3) Induction for Older Patients with AML or High-Risk MDS Is Well Tolerated and Results in Favorable Clinical Outcomes: The Panda Trial

Matthew J. Wieduwilt, MD PhD, Scott Thomas, PhD, Rebecca L. Olin, MD MSCE, Aaron C. Logan, MDPhD, Lloyd E. Damon, MD, Thomas G. Martin, III, MD, McNancy Kang, Peter H. Sayre, MD PhD, Wanda Boyer, NP,MSN, Karin ML Gaensler, MD, Kirsten Anderson, Pamela Munster, MD, Charalambos Andreadis, MD MSCE
Journal: Blood
Blood (2015) 126 (23): 1337.
https://doi.org/10.1182/blood.V126.23.1337.1337
Published: 2015
Journal Articles

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

Megan Murnane, M.Sc., Eugen Dhimolea, PhD, Ruojing Li, BS, Megan A. Bariteau, BSc, Diamond D. Wheeler, BS, Rosemary J. Akhurst, PhD, Aaron C. Logan, MD PhD, Pamela Munster, MD, Arun Wiita, MD PhD, Thomas G. Martin, III, MD, Jeffrey L. Wolf, MD PhD, Jun O. Liu, PhD, Constantine S. Mitsiades, MD PhD, Blake T. Aftab, PhD
Journal: Blood
Blood (2015) 126 (23): 503.
https://doi.org/10.1182/blood.V126.23.503.503
Published: 2015
Journal Articles

Interim Results of a Phase I Study of Lenalidomide (CC-5013) Plus Intraventricular/Intravenous Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

James L. Rubenstein, MD, PhD, Paul Formaker, Xiaomin Wang, PhD, Nianhang Chen, PhD, Michael Seider, MD, Pamela Munster, MD, Bertil Damato, MD, PhD
Journal: Blood
Blood (2014) 124 (21): 4470.
https://doi.org/10.1182/blood.V124.21.4470.4470
Published: 2014
Journal Articles

Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma

Clinical Trials & Observations
James L. Rubenstein, Jing Li, Lingjing Chen, Ranjana Advani, Jan Drappatz, Elizabeth Gerstner, Tracy Batchelor, Hendrikus Krouwer, James Hwang, Glenna Auerback, Cigall Kadoch, Clifford Lowell, Pamela Munster, Soonmee Cha, Marc A. Shuman, Lloyd E. Damon
Journal: Blood
Blood (2013) 121 (5): 745–751.
https://doi.org/10.1182/blood-2012-07-440974
Published: 2013
Includes: Supplemental data
Journal Articles

Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma

James L. Rubenstein, M.D., Ph.D., Lingjing Chen, Ph.D., Ranjana Advani, MD, Jan Drappatz, M.D., Elizabeth Gerstner, M.D., Tracy Batchelor, MD, Hendrikus Krouwer, M.D., Cigall Kadoch, BA, Pamela Munster, MD, Soonmee Cha, M.D., Marc A Shuman, MD, Lloyd E. Damon, MD
Journal: Blood
Blood (2011) 118 (21): 959.
https://doi.org/10.1182/blood.V118.21.959.959
Published: 2011
Journal Articles

ABCG2 expression, function, and promoter methylation in human multiple myeloma

Joel G. Turner, Jana L. Gump, Chunchun Zhang, James M. Cook, Douglas Marchion, Lori Hazlehurst, Pamela Munster, Michael J. Schell, William S. Dalton, Daniel M. Sullivan
Journal: Blood
Blood (2006) 108 (12): 3881–3889.
https://doi.org/10.1182/blood-2005-10-009084
Published: 2006